This trial is evaluating whether NNZ-2591 will improve 5 primary outcomes and 1 secondary outcome in patients with Chromosome Disorders. Measurement will happen over the course of 13 weeks.
This trial requires 20 total participants across 1 different treatment group
This trial involves a single treatment. NNZ-2591 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"As nnz-2591 has been found to protect rats from acute kidney injury, our studies indicated that nnz-2591 might be an effective inhibitor of neutrophil sequestration and tissue damage in acute lung injury after ischemia-reperfusion. Prospective studies will be needed to assess whether its clinical administration can improve the outcome of patients with acute lung injury." - Anonymous Online Contributor
"Syndromes account for more individuals with disability than anticipated in the literature. Syndromes are common presenting problems among US adults with a disability, and the syndrome a year may overestimate the proportion of the burden the disability imposes on the US population. Syndromes and their burden should be considered as an area to target in the disability paradigm in the US." - Anonymous Online Contributor
"The defining feature of a syndrome is that the clinical and research findings in its members are associated with the syndrome's molecular biology, and that the clinical and research findings are different from patients without the syndrome. The authors of the book discuss how syndromes result from interactions between genes and their environment.\n" - Anonymous Online Contributor
"The syndrome that results from the interaction of genetic, environmental, and psychological risk factors plays an important role in the persistence of symptoms such as mood and behavioral problems. This emphasizes the need for specific medical and behavioral treatment components for each syndrome. Nevertheless, the syndrome of a disorder alone cannot be cured." - Anonymous Online Contributor
"Common treatment for syndrome is medications, which are the first line treatment and usually ineffective. The treatments are primarily focused on symptoms and symptom relievers, while disease mechanisms are either not addressed or not well understood in the syndrome. Some syndromes may require more aggressive treatment of their symptomology." - Anonymous Online Contributor
"Syndromes are groups of syndromes that share a common symptom profile and/or behavioural trait. More than one syndrome can exist in the same patient. Syndromes can be identified through the diagnosis of their associated symptoms, if this allows for identification of a possible syndrome. This is the first instance encountered where a syndrome was encountered by a health professional when only symptom profiles of syndromes were known." - Anonymous Online Contributor
"Findings from a recent study of this study support the notion that the presence of symptoms may indicate an underlying cause and also that, in some cases, symptoms may be found alone without an associated cause. To confirm the presence of syndrome, clinical investigation should exclude a specific cause; once a cause is identified, it may be addressed by treating the cause rather than the syndrome." - Anonymous Online Contributor
"NNZ-2591 is a potent neuroprotective agent that is currently undergoing pre-clinical development for therapeutic use in animal models. In addition to the favorable profile of NNZ-2591, the results of this study clearly indicate that nnz-2591 will have an effective therapeutic profile in humans." - Anonymous Online Contributor
"Results from a recent paper of this study suggest that Nnz-2591 may be a new and effective agent for the treatment of the neurological symptoms of PD at an average oral dose of 3 mg/kg b. w. Tolerance to the observed neuroprotective properties of NNZ-2591 did not appear to be mediated by the usual mechanisms of action of the NMDA receptor antagonist, but may be due to unique and interesting structural features." - Anonymous Online Contributor
"A dose of 2 mg NNZ-2591 (in pill form) is appropriate for the study of parenteral antigens in subjects who are not immunocompromised and not allergic. The protocol was well tolerated and is effective, even in patients who are allergic or have severe allergies to antigens to which they are hypersensitive." - Anonymous Online Contributor
"When comparing the use of NNZ 2591 to other therapies, the use of the two drugs in combination results in significantly better outcomes for persons with depression than when only NNZ 2591 is used in conjunction with current therapies." - Anonymous Online Contributor
"The prevalence of syndrome increased at a younger age at diagnosis than suggested previously. The increase in detection at younger ages may have resulted from improvements in screening for the syndrome as a result of increasing public awareness and more frequent disease activity in younger people, and an improvement in diagnostic tools. Further studies are needed to verify that this younger presentation is real." - Anonymous Online Contributor